Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial
Study context
- Population
- STEMI patients with multivessel CAD and ≥1 non-IRA lesion with ≥50% stenosis by visual estimation; 50%-69% lesions assessed by fractional flow reserve (FFR), ≥70% revascularized without FFR
- Planned comparison
- Immediate vs in-hospital staged FFR-guided complete revascularisation
- Primary endpoint
- Composite of:
- All-cause death
- Non-fatal MI
- All unplanned revascularization
- Follow-up
- 1 year after randomization
Methodological detailsmulticentre, investigator-initiated, prospective, open-label, non-inferiority, 1:1 randomisation, Enrolment December 2019 to January 2024; primary endpoint follow-up to be completed January 2025, results expected mid-2025
- Multicentre
- Investigator-initiated
- Prospective
- Open-label
- Non-inferiority
- 1:1 randomisation
- Enrolment December 2019 to January 2024; primary endpoint follow-up to be completed January 2025, results expected mid-2025
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial. Am Heart J. Published 18 April 2024. doi:10.
Summarised from the published abstract; every number is checked against it